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Abstract
Background: While journals and reporting guidelines recommend the presentation of confidence intervals, many
authors adhere strictly to statistically significant testing. Our objective was to determine what proportions of not
statistically significant (NSS) cardiovascular trials include potentially clinically meaningful effects in primary outcomes
and if these are associated with authors’ conclusions.
Methods: Cardiovascular studies published in six high-impact journals between 1 January 2010 and 31 December
2014 were identified via PubMed. Two independent reviewers selected trials with major adverse cardiovascular
events (stroke, myocardial infarction, or cardiovascular death) as primary outcomes and extracted data on trial
characteristics, quality, and primary outcome. Potentially clinically meaningful effects were defined broadly as a
relative risk point estimate ≤0.94 (based on the effects of ezetimibe) and/or a lower confidence interval ≤0.75
(based on the effects of statins).
Results: We identified 127 randomized trial comparisons from 3200 articles. The primary outcomes were statistically
significant (SS) favoring treatment in 21% (27/127), NSS in 72% (92/127), and SS favoring control in 6% (8/127). In
61% of NSS trials (56/92), the point estimate and/or lower confidence interval included potentially meaningful
effects. Both point estimate and confidence interval included potentially meaningful effects in 67% of trials (12/18)
in which authors’ concluded that treatment was superior, in 28% (16/58) with a neutral conclusion, and in 6% (1/16)
in which authors’ concluded that control was superior. In a sensitivity analysis, 26% of NSS trials would include
potential meaningful effects with relative risk thresholds of point estimate ≤0.85 and/or a lower confidence
interval ≤0.65.
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Conclusions: Point estimates and/or confidence intervals included potentially clinically meaningful effects in
up to 61% of NSS cardiovascular trials. Authors’ conclusions often reflect potentially meaningful results of NSS
cardiovascular trials. Given the frequency of potentially clinical meaningful effects in NSS trials, authors should be
encouraged to continue to look beyond significance testing to a broader interpretation of trial results.
Keywords: Cardiovascular, Randomized controlled trials, Statistical significance, Clinical significance, Confidence
intervals, Conclusions
Background
The preferred reporting of clinical outcomes in randomized
controlled trials (RCTs) is described in the Consolidated
Standards of Reporting Trials (CONSORT) statement [1].
Within CONSORT the use of confidence intervals is
emphasized in preference to p-values. Confidence
intervals describe the precision of the estimate and
“are especially valuable in relation to differences that
do not meet conventional statistical significance, for
which they often indicate that the result does not rule
out an important clinical difference” [1]. Editorials
dating back almost 40 years have encouraged authors
to use confidence intervals to describe the results of
their studies rather than simply reporting the findings
as statistically significant or not [2–4]. Despite this,
the use of p-values in published articles remains
approximately seven times more common than confi-
dence intervals [5]. Furthermore, confidence intervals
are often used in a manner similar to p-values, to
dichotomize outcomes as statistically significant (SS) or
not. We have previously written about three important
clinical controversies resulting from this dichotomous
activity [6].
Interpretation of trial results when primary outcomes
are not statistically significant (NSS) is challenging. In
particular, it can be difficult putting the potential clinical
relevance of the NSS effect and confidence intervals in
context of the entire study results. Boutron and colleagues
demonstrated that authors often place a favorable “spin”
(positive portrayal) on trial results when the primary out-
come is NSS [7]. Such spin occurred in 58% of abstract
conclusions, 50% of main text conclusions, and 18% of
titles. Others have similarly reported spin in RCTs evaluat-
ing wound care [8] and surgical modalities [9, 10].
Although promotion of results may be common in NSS
trial reporting, the evaluation assumes that NSS results
demonstrate no potentially clinically meaningful effect.
For these reasons we examined the primary outcomes
and conclusions of RCTs in six major medical journals.
We had two primary questions: (1) How often do the
point estimates and confidence intervals of the primary
outcome of NSS and SS trials include potentially clinically
meaningful effects? and (2) Are the authors’ conclusions
in the abstract of NSS trials influenced by potentially
clinically meaningful point estimates and confidence inter-
vals? We focused specifically on cardiovascular trials with
major adverse cardiovascular events (MACE) because
these are established, objective, patient-oriented outcomes
that overlap between trials. Additionally, in large cardio-
vascular trials with hard clinical endpoints, statistical
significance can be difficult to attain but the results have
high clinical relevance. We hypothesized that authors of
cardiovascular trials may discount potentially clinically
meaningful effects identified in the confidence intervals
and/or point estimates when the results are NSS.
Methods
We followed the basic approach described in PRISMA
[11] because there is no agreed on methodology for this
type of study.
Eligibility and information sources
We included all cardiovascular RCTs of superiority de-
sign that evaluated preventive or interventional therapies
regardless of the nature of the interventions – including
medication, surgery, models of care, and lifestyle change.
All comparators were valid, including placebo, active
control, and no intervention. The primary outcome had
to include at least one MACE: myocardial infarction,
stroke, or cardiovascular death. We used PubMed to
identify relevant trials from five high-impact general
medical journals and one high-impact specialty journal:
New England Journal of Medicine (N Engl J Med),
Lancet, Journal of the American Medical Association
(JAMA), British Medical Journal (BMJ), Annals of
Internal Medicine (Ann Intern Med), and Circulation.
Study search and selection
Between 17 March and 14 April 2015, we searched
PubMed for papers using the full journal title (and
abbreviation, if present) with PubMed limits for RCTs
and date (1 January 2010 to 31 December 2014). In the
case of Circulation, the term circulation could relate to
medical/physiologic issues in addition to the journal, so
we restricted the search field to “Journal”. For the other
five journals we did not apply any search restrictions in
order to minimize the unlikely chance of missing
relevant articles. For each journal, two authors (from
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VK, SK, EB, and GMA) independently evaluated and
selected studies for inclusion. We excluded studies of
subgroups, re-analyses, and studies that were either
extensions or follow-ups from previously published trials
to avoid including the same data more than once. We also
excluded non-inferiority designed studies because authors’
interpretations and conclusions of non-inferiority results
are broader, and this would add complexity to our
interpretation of abstract conclusions. Disagreements for
inclusion were resolved by consensus.
Data extraction and management
Two authors (CF with VK or SK) independently ex-
tracted data from the trials. Disagreement was resolved
with consensus or third-party review (GMA).
Data extraction on study characteristics included
citation, type of intervention and control, primary versus
secondary prevention population, mean age in study,
and percentage of males studied. Data on traditional risk
of bias included allocation concealment, blinding,
analysis (intention to treat or per protocol), and with-
drawals. We also collected data on funding, and whether
the trial was stopped early (if so, why) or extended. Data
related to the primary outcome included the clinical
endpoint, number of subjects in each study arm, number
with the outcomes in each group, point estimate, confi-
dence intervals, and p-values.
To evaluate the authors’ conclusions, the abstract
conclusion was rated using a method derived from Als-
Nielsen and colleague’s technique [12]. We condensed
the score from six to three possible conclusions: treat-
ment superior, neutral, or control superior.
Assessing potentially meaningful effects
To assess if the primary outcome of an NSS trial
included potentially meaningful effects, we focused on
the point estimate and lower confidence interval. The
margins of potentially clinically meaningful effect are
undoubtedly debatable. Over 20 years ago, authors sug-
gested that potentially clinically meaningful effects could
be 25% or 50% relative risk reductions [13]. More
recently, trials showing a relative risk reduction of 6%
for ezetimibe [14] and 14% for empagliflozin [15] have
been greeted with enthusiasm [16, 17]. We selected our
margins of potentially meaningful effect liberally to be
broad and inclusive, thereby ruling out what is likely not
a clinically meaningful effect. We decided that the
smallest potentially clinically meaningful effect was a 6%
relative risk reduction or a 0.94 relative risk, as reported
by the IMPROVE-IT trial for ezetimibe [14]. For lower
confidence intervals to include potentially meaningful
effects, we selected a 25% relative risk reduction or 0.75
relative risk described in meta-analyses of statin trials
[18], an established clinical therapy.
Analysis of results
Study characteristics and potential biases are presented
descriptively. Relative effect estimates including relative
risks, hazard ratios, rate ratios, and odds ratios were
used for primary analysis. If not provided, relative risks
and 95% confidence intervals were calculated.
Trials were initially categorized into three groups
based on the statistical testing of the primary outcome:
SS trials favoring control, SS trials favoring treatment,
and NSS trials. Statistical significance was determined by
hypothesis testing via the p-value first and, if not avail-
able, we determined if the confidence interval excluded
1 (the line of no-effect).
To analyze and describe the results, the primary
outcomes for all RCTs were presented on a forest
plot with the potentially clinically meaningful thresh-
olds for point estimate (≤0.94) and confidence interval
(≤0.75) indicated. We categorized NSS trials as having
(1) both the lower confidence interval and point
estimate include potentially meaningful effects; (2)
either the lower confidence interval or point estimate
include a potentially meaningful effect; or (3) neither
the lower confidence interval nor point estimate
include a potentially meaningful effect. Among NSS
trials, results were further stratified according to au-
thors’ conclusions.
We used chi-square and independent samples median
test to examine if selected factors were associated with
authors’ conclusions in NSS trials. Factors compared
included type of control used in the trials, funding
(industry, public, or mixed), point estimates, and lower
confidence intervals.
Sensitivity analyses
We performed sensitivity analyses to examine the effect of
some key variables on the proportion of NSS trials with
potentially clinically meaningful effect. Because smaller
trials may be expected to have broader confidence inter-
vals, we performed an analysis of trials with <2000
patient-years and those with ≥2000 patient-years. Because
primary prevention trials will have smaller absolute bene-
fits for a given relative benefit, we performed an analysis
of primary versus secondary prevention trials.
To determine how sensitive the results were to the
threshold of potential clinically meaningful effects, we
increased the potentially meaningful relative risk reduc-
tion threshold for point estimates to ≥15% (or ≤0.85
relative risk) and for lower confidence intervals to ≥35%
(or ≤0.65 relative risk).
Results
Study inclusion and characteristics
The flow of study exclusion and inclusion is detailed in
Fig. 1. Of the original 3200 studies identified in our
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search, 127 RCTs met inclusion criteria. Agreement for
study selection was 97% and for data extraction was
93%. General characteristics and risk of bias of included
studies are outlined in Table 1 and the full list of the
studies is included in Additional file 1. Secondary
prevention trials (85%, 108/127) and community-based
trials (58%, 74/127) were most common. The primary
outcome included a range of one to ten combined
outcomes (median, three) with myocardial infarction
(80%), stroke (65%), and cardiovascular death (50%)
being the most common. Overall, study quality was
good: for example, 77% (98/127) described allocation
concealment and 94% (119/127) performed intention-
to-treat analysis. Most trials (75%, 95/127) were com-
pleted as planned but 22% (28/127) were stopped
early for varying reasons (usually harm or futility)
and 3% (4/127) were extended.
Statistical significance of primary outcome and conclusions
Figure 2 outlines the flow of study outcomes with
categorization by statistical significance for the primary
outcome and authors’ conclusions. The primary outcome
was SS favoring treatment in 21% of trials (27/127) and all
concluded treatment was superior. The primary outcome
was NSS in 72% of trials (92/127), of which 63% (58/92)
had a neutral conclusion, 20% (18/92) concluded treat-
ment was superior, and 17% (16/92) concluded control
was superior. The primary outcome was SS favoring con-
trol in 6% (8/127) and all concluded control was superior.
Potentially clinically meaningful effects by statistical
significance
Figure 3 provides the forest plot of all primary outcomes
organized by statistical significance and if the confidence
intervals and/or point estimates included potentially
Fig. 1 Study flow
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meaningful effects. Careful inspection of the forest plot
reveals that a number of the NSS trials had lower confi-
dence intervals and point estimates that appear similar
to the effects in many of the SS trials. Among NSS trials,
in 32% (29/92) both the lower confidence interval and
point estimate included potentially meaningful effects,
while in 29% (27/92) only one of the two included a po-
tentially meaningful effect. Neither the lower confidence
interval nor point estimate included potentially mean-
ingful effects in 39% of NSS trials (36/92).
Potentially clinically meaningful effects and authors’
conclusions in not statistically significant trials
Figure 4 shows the findings based on authors’ conclusions
and whether the lower confidence intervals and/or point
estimates of the primary outcomes included potentially
meaningful effects. The lower confidence interval and
point estimate included potentially meaningful effects in
67% of trials (12/18) with conclusions that treatment was
superior compared to 6% of trials (1/16) with conclusions




New England Journal of Medicine 65 (51)
Lancet 23 (18)
Journal of the American Medical Association 20 (16)
British Medical Journal 5 (4)
















Median age (interquartile range), years 63.8 (61.5–66.5)
Percent males (interquartile range) 72.0 (60.4–78.0)
Study size and duration
Median study size (interquartile range) 3020 (1319–8521)
Median study duration (interquartile range), months 24.0 (8.3–45.3)
Primary outcome included (median 3, range 1–10), n (%)
Myocardial infarction 101 (80)
Stroke 83 (65)
Cardiovascular death 64 (50)
Overall death 51 (40)
Revascularization 31 (25)
Heart failure 22 (17)
Othera 37 (29)
Risk of bias, n (%)
Planned trial duration
Completed as planned 95 (75)
Extended 4 (3)
Stopped for benefit 8 (6)
Stopped for harm 10 (8)
Stopped for futility 9 (7)
Stopped for financial reasons 1 (1)
Table 1 Study characteristics and risk of bias of the 127 included









Intention to treat 119 (94)
Modified intention to treat 7 (6)
Per protocol 1 (1)
Sample size estimation
Estimation attained 83 (65)
Estimation missed 38 (30)
No estimation given 6 (5)
Withdrawal
Number provided 115 (91)





Not described 1 (1)
*Examples of other include stem cells and continuous positive airway pressure
aOther includes angina, thromboembolism, stent failure, cardiac arrest, renal
outcomes, shock, peripheral vascular event, bleeding, arrhythmia, pericardial
tamponade, respiratory failure, severe left ventricular dysfunction requiring
mechanical support, hypertension, and/or aortic insufficiency
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that control was superior. Neither the lower confidence
interval nor point estimate included potentially meaning-
ful effects in 11% of trials (2/18) with conclusions that
treatment was superior compared to 63% of trials (10/16)
with conclusions that control was superior. The point esti-
mates and lower confidence intervals of neutral authors’
conclusions were distributed relatively evenly.
Factors associated with authors’ conclusions
Table 2 shows NSS trial abstract conclusions compared
to selected study characteristics, including the type of
comparator used (placebo or active), funding (industry
or public), point estimate (median and threshold), and
lower confidence interval (median and threshold). There
was no association between conclusions and type of com-
parator or funding. Both median point estimates and me-
dian lower confidence intervals decline as authors’
conclusions change from control superior to neutral to
treatment superior (both p ≤ 0.006). Additionally, the clin-
ically meaningful thresholds for point estimates and lower
confidence intervals were statistically significantly associ-
ated with authors’ conclusion (p ≤ 0.002). These findings
consistently show a similar association for NSS trials:
lower point estimates and/or confidence intervals that
suggest potentially clinical effects are associated with
authors’ concluding that treatment is superior.
Sensitivity analyses
Table 3 shows the sensitivity analyses. Subgroups of trial
size or primary and secondary prevention generally had
similar proportions of trials with potentially meaningful
effects. The only exception was the trial size subgroup
examining the proportion of NSS trials with confidence
intervals that suggested potentially meaningful effects:
71% (25/35) for smaller NSS trials with <2000 patient-
years versus 28% (16/57) for larger NSS trials with ≥2000
patient-years. The proportion of larger NSS trials with a
point estimate and/or confidence interval including poten-
tially meaningful effects was 53% (30/57).
Lastly, NSS trials were re-examined using increased
potentially clinically meaningful thresholds. The
increased thresholds were a relative risk reduction of
≥15% for point estimates and ≥35% for lower confidence
intervals. In 15% of NSS trials (14/92) both the increased
point estimate and confidence interval included poten-
tially meaningful effects, in 11% (10/92) only one of the
two included a potentially meaningful effect, and in 74%
(68/92) neither threshold was met.
Discussion
In 61% of NSS cardiovascular trials, the primary out-
come had a confidence interval that included an effect
similar to or better than statin therapy (relative risk
reduction ≥25%) and/or a point estimate similar to or
better than ezetimibe (≥6%). These results suggest that if
we were to strictly focus on a dichotomous finding of
whether results are SS or NSS, we run the risk of dis-
missing a treatment in almost two thirds of NSS trials
that could potentially have meaningful effects. Further-
more, about one third of NSS trials had even higher
probability of potentially clinically meaningful effects
because both confidence intervals and point estimates
included potentially meaningful effects. In fact, visual
inspection of Fig. 2 shows the distribution of the effects
is very similar between SS trials favoring treatment and
NSS trials when both confidence interval and point
estimates include potential meaningful effects. This
further suggests that strict adherence to an arbitrary
threshold for statistical significance may serve poorly as
a judgment of treatment benefit.
Within NSS trials, authors’ conclusions were associ-
ated with the potentially meaningful effects in the confi-
dence intervals and point estimates. For example, both
the point estimate and confidence intervals included po-
tentially meaningful effects in 67% of NSS trials in which
the authors concluded treatment was superior. In con-
trast, both the point estimate and confidence intervals
included potentially meaningful effects in only 6% of
NSS in which the authors’ concluded control was super-
ior. Past research suggested that just over half of NSS
studies have conclusions that are unjustifiably positive
and inconsistent with the results [7]. However, our study
Fig. 2 Flow of trial primary outcome including presence of statistical significance and abstract conclusion
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suggests that some of these favorable interpretations
may relate to potentially meaningful benefits suggested
in the confidence intervals and/or point estimates. Given
this and the recommendations of CONSORT regarding
the presentation of results [1], future research evaluating
authors’ interpretations or conclusions of NSS trials
should assess trial outcomes beyond statistical signifi-
cance testing.
Fig. 3 Forest plot of trial primary outcomes organized by statistically significant testing and if potentially clinical meaningful effects are indicated
by the point estimates (≤0.94) and/or the confidence intervals (≤0.75). RCT randomized controlled trial. * Not statistically significant as p-value
adjusted for multiple comparisons
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Potentially meaningful effects in the point estimates
and confidence intervals are not the only factors in-
fluencing authors’ conclusions. For example, 28% of
NSS trials with a neutral conclusion had both a lower
confidence interval and point estimate suggestive of
potentially meaningful effects. Perhaps these authors
are basing their conclusions solely on statistical sig-
nificance but it is also possible that other elements of
the trial results or intervention play a role: adverse
events, costs, and secondary outcomes are all poten-
tially relevant.
Our results were sensitive to two possibly predictable
factors. First, trials of smaller size frequently have less pre-
cision in the estimate and thus broader confidence inter-
vals. Within our study, this could result in more of the
smaller trials having lower confidence intervals crossing a
potentially meaningful threshold. This did occur but most
of the trials included in this review were large. Therefore,
Fig. 4 The proportion of lower confidences intervals and/or point estimates that suggest potentially meaningful effects within conclusions from
not statistically significant trials. Potentially meaningful lower confidence interval ≤0.75 relative risk; potentially meaningful point estimate ≤0.94
relative risk
Table 2 Abstract conclusions of included not statistically significant trials with a superiority design categorized by study characteristics
Authors’ conclusion in the abstract p-value
Control superior Neutral Treatment superior
Number of studies 16 58 18
Comparator
Placebo/nothing: 49 studies (%) 12 (24) 29 (59) 8 (16) 0.15a
Standard/active comparator: 43 studies (%) 4 (9) 29 (67) 10 (23)
Funding
Industry: 37 studies (%) 9 (24) 21 (57) 7 (19) 0.14a
Mixed: 35 studies (%) 7 (20) 20 (57) 8 (23)
Public: 20 studies (%) 0 17 (85) 3 (15)
Point estimate
Median (interquartile range) 0.99 (0.96–1.09) 0.95 (0.90–1.01) 0.88 (0.83–0.98) 0.006b
Point estimate >0.94: 48 studies (%) 14 (29) 29 (60) 5 (10) 0.002a
Point estimate ≤0.94: 44 studies (%) 2 (5) 29 (66) 13 (30)
Lower confidence interval
Median (interquartile range) 0.84 (0.73–0.89) 0.79 (0.66–0.86) 0.66 (0.57–0.69) 0.005b
Confidence interval >0.75: 51 studies (%) 11 (22) 37 (73) 3 (6) 0.001a
Confidence interval ≤0.75: 41 studies (%) 5 (12) 21 (51) 15 (37)
aChi-square
bIndependent samples median test
Allan et al. BMC Medicine  (2017) 15:58 Page 8 of 10
the proportion of NSS trials in which either the point esti-
mate and/or the confidence interval included potentially
meaningful effects was only slightly lower in larger trials
(having ≥2000 patient-years) than overall (53% versus
61%, respectively). Second, modification of the thresholds
of potentially clinically meaningful effects foreseeably re-
duced the proportion of trials with potentially meaningful
effects. The proportion of NSS trials in which either the
point estimate and/or the confidence interval included po-
tentially meaningful effects was 61% in our primary ana-
lysis but fell to 26% when the relative risk reduction
thresholds were increased to ≥15% for point estimates and
≥35% for confidence intervals. However, even with these
stricter criteria, a quarter of all NSS cardiovascular trials
found potentially meaningful effects.
Despite our findings, it is important not to over-
interpret our results and assume that we are suggesting
that a 6% relative risk reduction is a meaningful effect in
all populations. Nor would we suggest all researchers
use these thresholds for sample size estimation and/or
extended or repeated studies until these small benefits
are entirely ruled out. All interventions, and the trials
assessing their clinical value, need to be considered in
the boarder context of many relevant factors, including
overall risk of the primary outcome, adverse events,
costs, inconvenience, and alternative interventions. We
hope this paper can draw attention to the need to use
confidence intervals and describe potentially meaningful
effects. Fortunately, it appears that a number of authors
are already doing this. Moreover, we support the advice
[19] that authors and evidence-users move away from
the dogmatic adherence to hypothesis testing that leads
some to believe that a p-value of 0.049 means a positive
trial and treatment works while a p-value of 0.051 means
a negative trial and treatment does not work.
There are some notable limitations to our study. First,
there are many factors involved in how authors interpret
their research but our study focused only on point
estimates and confidence intervals of primary outcomes.
Second, we focused on cardiovascular trials with hard
clinical (MACE) endpoints and so confirmation is
required to determine if results would be similar for re-
search in other conditions like chronic obstructive
pulmonary disease or infectious disease. Third, our
definitions of potentially clinically meaningful effects may
be seen as arbitrary or too generous. There is no agreed-
on minimal clinically important effect for MACE out-
comes so we derived our definition from established ther-
apies although some will certainly feel they are too
generous. We used somewhat liberal thresholds because
our goal was to determine if results included any “poten-
tially” clinically meaningful effects but we also performed
a sensitivity analysis with stricter criteria. While some will
see these cut-offs as arbitrary, a goal of this paper is to re-
flect on the rigid adherence to the 0.05 statistic signifi-
cance threshold, which itself can be considered arbitrary.
Fourth, we used relative margins. The use of relative mar-
gins allows for more easy comparison across trials because
any assessment of absolute effects must also account for
time. Fifth, although we assessed authors’ conclusions by
focusing on abstract conclusions, this is a previous
method of rating conclusions [12] and abstract conclusion
is the most likely location for promotion of results [7]. It
should also be noted that the abstract conclusions, like
any part of the articles, may have been modified through
the peer-review process and editorial recommendations. It
is not possible to clarify to what, if any, degree this oc-
curred but we suspect it is small.
Conclusions
In up to 61% of NSS cardiovascular trials, the primary
outcome has a point estimate and/or confidence interval
that includes potentially clinically meaningful effects.
Furthermore, among the NSS cardiovascular trials, au-
thors’ conclusions were positively associated with point
estimates and lower confidence intervals that suggest
greater potential effects. In fact, both the point estimates
and confidence intervals included potentially meaningful
Table 3 Sensitivity analysis of not statistically significant randomized controlled trials




≤0.94 >0.94 ≤0.75 >0.75
Study size (in patient years) <2000 patient-years
(n = 35)
16 (46%) 19 (54%) 25 (71%) 10 (29%)
≥2000 patient-years
(n = 57)
28 (49%) 29 (51%) 16 (28%) 41 (72%)
Primary versus secondary prevention Primary
(n = 13)
5 (38%) 8 (62%) 5 (38%) 8 (62%)
Secondary
(n = 79)
39 (49%) 40 (51%) 36 (46%) 43 (54%)
≤0.85 >0.85 ≤0.65 >0.65
Increase in potentially clinically meaningful thresholds (n = 92) 16 (17%) 76 (83%) 22 (24%) 70 (76%)
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effects in 67% of trials (12/18) in which the authors
concluded that treatment was superior, compared to
only 6% (1/16) in which authors concluded that control
was superior. Given the frequency of NSS cardiovascular
trials, it is reassuring that many authors look beyond stat-
istical significance testing and consider the potentially
meaningful clinical effects of their results. Additionally,
journals and evidence-users should be encouraged, as
directed by CONSORT, to consider point estimates and
confidence intervals in the context of potentially clinically
meaningful effects and not strictly for hypothesis and
statistical significance testing.
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